Novo Integrated Sciences, Inc.
Novo Integrated Sciences, Inc. NVOS Peers
See (NVOS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVOS | $0.00 | +175.00% | 43.4K | N/A | -$1.33 | N/A |
| HCA | $368.78 | -0.65% | 88.7B | 16.61 | $22.20 | +0.75% |
| FMS | $28.49 | -0.44% | 16.7B | 23.54 | $1.21 | +2.38% |
| THC | $164.35 | -0.01% | 15.3B | 10.22 | $16.08 | N/A |
| SOLV | $74.46 | +0.89% | 12.9B | 34.31 | $2.17 | N/A |
| EHC | $120.48 | -0.36% | 12.1B | 25.00 | $4.82 | +0.55% |
| UHS | $170.34 | -0.43% | 11B | 9.57 | $17.80 | +0.47% |
| DVA | $137.83 | +1.26% | 10.4B | 13.66 | $10.09 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| ENSG | $152.74 | +0.99% | 8.8B | 28.87 | $5.29 | +0.16% |
Stock Comparison
NVOS vs HCA Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, HCA has a market cap of 88.7B. Regarding current trading prices, NVOS is priced at $0.00, while HCA trades at $368.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas HCA's P/E ratio is 16.61. In terms of profitability, NVOS's ROE is -1.20%, compared to HCA's ROE of -2.36%. Regarding short-term risk, NVOS is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs FMS Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, FMS has a market cap of 16.7B. Regarding current trading prices, NVOS is priced at $0.00, while FMS trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas FMS's P/E ratio is 23.54. In terms of profitability, NVOS's ROE is -1.20%, compared to FMS's ROE of +0.04%. Regarding short-term risk, NVOS is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs THC Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, THC has a market cap of 15.3B. Regarding current trading prices, NVOS is priced at $0.00, while THC trades at $164.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas THC's P/E ratio is 10.22. In terms of profitability, NVOS's ROE is -1.20%, compared to THC's ROE of +0.37%. Regarding short-term risk, NVOS is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs SOLV Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, SOLV has a market cap of 12.9B. Regarding current trading prices, NVOS is priced at $0.00, while SOLV trades at $74.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas SOLV's P/E ratio is 34.31. In terms of profitability, NVOS's ROE is -1.20%, compared to SOLV's ROE of +0.12%. Regarding short-term risk, NVOS is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs EHC Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, EHC has a market cap of 12.1B. Regarding current trading prices, NVOS is priced at $0.00, while EHC trades at $120.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas EHC's P/E ratio is 25.00. In terms of profitability, NVOS's ROE is -1.20%, compared to EHC's ROE of +0.25%. Regarding short-term risk, NVOS is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs UHS Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, UHS has a market cap of 11B. Regarding current trading prices, NVOS is priced at $0.00, while UHS trades at $170.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas UHS's P/E ratio is 9.57. In terms of profitability, NVOS's ROE is -1.20%, compared to UHS's ROE of +0.18%. Regarding short-term risk, NVOS is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs DVA Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, DVA has a market cap of 10.4B. Regarding current trading prices, NVOS is priced at $0.00, while DVA trades at $137.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas DVA's P/E ratio is 13.66. In terms of profitability, NVOS's ROE is -1.20%, compared to DVA's ROE of +3.94%. Regarding short-term risk, NVOS is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs OSH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, NVOS is priced at $0.00, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas OSH's P/E ratio is -17.65. In terms of profitability, NVOS's ROE is -1.20%, compared to OSH's ROE of +4.64%. Regarding short-term risk, NVOS is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs ENSG Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, ENSG has a market cap of 8.8B. Regarding current trading prices, NVOS is priced at $0.00, while ENSG trades at $152.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas ENSG's P/E ratio is 28.87. In terms of profitability, NVOS's ROE is -1.20%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, NVOS is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs CHE Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, CHE has a market cap of 8.1B. Regarding current trading prices, NVOS is priced at $0.00, while CHE trades at $552.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas CHE's P/E ratio is 26.76. In terms of profitability, NVOS's ROE is -1.20%, compared to CHE's ROE of +0.26%. Regarding short-term risk, NVOS is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs LHCG Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, NVOS is priced at $0.00, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas LHCG's P/E ratio is 82.83. In terms of profitability, NVOS's ROE is -1.20%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, NVOS is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs OPCH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, OPCH has a market cap of 5.2B. Regarding current trading prices, NVOS is priced at $0.00, while OPCH trades at $31.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas OPCH's P/E ratio is 25.46. In terms of profitability, NVOS's ROE is -1.20%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, NVOS is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AMED Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AMED has a market cap of 3.2B. Regarding current trading prices, NVOS is priced at $0.00, while AMED trades at $97.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AMED's P/E ratio is 34.89. In terms of profitability, NVOS's ROE is -1.20%, compared to AMED's ROE of +0.10%. Regarding short-term risk, NVOS is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs SGRY Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, SGRY has a market cap of 3B. Regarding current trading prices, NVOS is priced at $0.00, while SGRY trades at $23.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas SGRY's P/E ratio is -15.14. In terms of profitability, NVOS's ROE is -1.20%, compared to SGRY's ROE of -0.10%. Regarding short-term risk, NVOS is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs ADUS Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, ADUS has a market cap of 2.1B. Regarding current trading prices, NVOS is priced at $0.00, while ADUS trades at $114.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas ADUS's P/E ratio is 25.89. In terms of profitability, NVOS's ROE is -1.20%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, NVOS is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs LFST Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, LFST has a market cap of 2B. Regarding current trading prices, NVOS is priced at $0.00, while LFST trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas LFST's P/E ratio is -57.44. In terms of profitability, NVOS's ROE is -1.20%, compared to LFST's ROE of -0.02%. Regarding short-term risk, NVOS is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs SEM Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, SEM has a market cap of 2B. Regarding current trading prices, NVOS is priced at $0.00, while SEM trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas SEM's P/E ratio is 24.52. In terms of profitability, NVOS's ROE is -1.20%, compared to SEM's ROE of +0.10%. Regarding short-term risk, NVOS is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs ACHC Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, ACHC has a market cap of 1.9B. Regarding current trading prices, NVOS is priced at $0.00, while ACHC trades at $21.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas ACHC's P/E ratio is 10.34. In terms of profitability, NVOS's ROE is -1.20%, compared to ACHC's ROE of +0.06%. Regarding short-term risk, NVOS is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs ARDT Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, ARDT has a market cap of 1.8B. Regarding current trading prices, NVOS is priced at $0.00, while ARDT trades at $12.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas ARDT's P/E ratio is 7.69. In terms of profitability, NVOS's ROE is -1.20%, compared to ARDT's ROE of +0.24%. Regarding short-term risk, NVOS is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AMEH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, NVOS is priced at $0.00, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AMEH's P/E ratio is 39.25. In terms of profitability, NVOS's ROE is -1.20%, compared to AMEH's ROE of +0.07%. Regarding short-term risk, NVOS is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs BKD Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, BKD has a market cap of 1.6B. Regarding current trading prices, NVOS is priced at $0.00, while BKD trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas BKD's P/E ratio is -6.48. In terms of profitability, NVOS's ROE is -1.20%, compared to BKD's ROE of -0.96%. Regarding short-term risk, NVOS is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs NHC Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, NHC has a market cap of 1.6B. Regarding current trading prices, NVOS is priced at $0.00, while NHC trades at $102.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas NHC's P/E ratio is 14.76. In terms of profitability, NVOS's ROE is -1.20%, compared to NHC's ROE of +0.11%. Regarding short-term risk, NVOS is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs ASTH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, ASTH has a market cap of 1.2B. Regarding current trading prices, NVOS is priced at $0.00, while ASTH trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas ASTH's P/E ratio is 34.16. In terms of profitability, NVOS's ROE is -1.20%, compared to ASTH's ROE of +0.07%. Regarding short-term risk, NVOS is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs BKDT Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, NVOS is priced at $0.00, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas BKDT's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to BKDT's ROE of -0.96%. Regarding short-term risk, NVOS is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs MD Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, MD has a market cap of 1.2B. Regarding current trading prices, NVOS is priced at $0.00, while MD trades at $13.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas MD's P/E ratio is -13.81. In terms of profitability, NVOS's ROE is -1.20%, compared to MD's ROE of -0.11%. Regarding short-term risk, NVOS is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs USPH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, NVOS is priced at $0.00, while USPH trades at $77.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas USPH's P/E ratio is 35.53. In terms of profitability, NVOS's ROE is -1.20%, compared to USPH's ROE of +0.06%. Regarding short-term risk, NVOS is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs HCSG Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, HCSG has a market cap of 1.1B. Regarding current trading prices, NVOS is priced at $0.00, while HCSG trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas HCSG's P/E ratio is 27.11. In terms of profitability, NVOS's ROE is -1.20%, compared to HCSG's ROE of +0.08%. Regarding short-term risk, NVOS is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs PNTG Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, PNTG has a market cap of 981.7M. Regarding current trading prices, NVOS is priced at $0.00, while PNTG trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas PNTG's P/E ratio is 37.47. In terms of profitability, NVOS's ROE is -1.20%, compared to PNTG's ROE of +0.11%. Regarding short-term risk, NVOS is more volatile compared to PNTG. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AVAH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AVAH has a market cap of 959.9M. Regarding current trading prices, NVOS is priced at $0.00, while AVAH trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AVAH's P/E ratio is 164.00. In terms of profitability, NVOS's ROE is -1.20%, compared to AVAH's ROE of -0.12%. Regarding short-term risk, NVOS is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AGL Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AGL has a market cap of 898.3M. Regarding current trading prices, NVOS is priced at $0.00, while AGL trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AGL's P/E ratio is -3.50. In terms of profitability, NVOS's ROE is -1.20%, compared to AGL's ROE of -0.44%. Regarding short-term risk, NVOS is more volatile compared to AGL. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AMN Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AMN has a market cap of 838.4M. Regarding current trading prices, NVOS is priced at $0.00, while AMN trades at $21.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AMN's P/E ratio is -5.06. In terms of profitability, NVOS's ROE is -1.20%, compared to AMN's ROE of -0.21%. Regarding short-term risk, NVOS is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs EHAB Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, EHAB has a market cap of 502.3M. Regarding current trading prices, NVOS is priced at $0.00, while EHAB trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas EHAB's P/E ratio is -3.58. In terms of profitability, NVOS's ROE is -1.20%, compared to EHAB's ROE of -0.31%. Regarding short-term risk, NVOS is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs INNV Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, INNV has a market cap of 496.8M. Regarding current trading prices, NVOS is priced at $0.00, while INNV trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas INNV's P/E ratio is -15.33. In terms of profitability, NVOS's ROE is -1.20%, compared to INNV's ROE of -0.12%. Regarding short-term risk, NVOS is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs TALKW Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, TALKW has a market cap of 476.2M. Regarding current trading prices, NVOS is priced at $0.00, while TALKW trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas TALKW's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to TALKW's ROE of -0.04%. Regarding short-term risk, NVOS is more volatile compared to TALKW. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AUNA Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AUNA has a market cap of 470.7M. Regarding current trading prices, NVOS is priced at $0.00, while AUNA trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AUNA's P/E ratio is 10.10. In terms of profitability, NVOS's ROE is -1.20%, compared to AUNA's ROE of +0.07%. Regarding short-term risk, NVOS is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs TALK Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, TALK has a market cap of 470.2M. Regarding current trading prices, NVOS is priced at $0.00, while TALK trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas TALK's P/E ratio is 140.50. In terms of profitability, NVOS's ROE is -1.20%, compared to TALK's ROE of -0.04%. Regarding short-term risk, NVOS is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs SNDA Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, SNDA has a market cap of 458.1M. Regarding current trading prices, NVOS is priced at $0.00, while SNDA trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas SNDA's P/E ratio is -6.69. In terms of profitability, NVOS's ROE is -1.20%, compared to SNDA's ROE of -0.53%. Regarding short-term risk, NVOS is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs CCRN Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, CCRN has a market cap of 452.1M. Regarding current trading prices, NVOS is priced at $0.00, while CCRN trades at $13.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas CCRN's P/E ratio is -25.54. In terms of profitability, NVOS's ROE is -1.20%, compared to CCRN's ROE of -0.04%. Regarding short-term risk, NVOS is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs CYH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, CYH has a market cap of 444.8M. Regarding current trading prices, NVOS is priced at $0.00, while CYH trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas CYH's P/E ratio is -0.91. In terms of profitability, NVOS's ROE is -1.20%, compared to CYH's ROE of +0.30%. Regarding short-term risk, NVOS is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs CMPS Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, CMPS has a market cap of 431.7M. Regarding current trading prices, NVOS is priced at $0.00, while CMPS trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas CMPS's P/E ratio is -2.34. In terms of profitability, NVOS's ROE is -1.20%, compared to CMPS's ROE of -0.72%. Regarding short-term risk, NVOS is more volatile compared to CMPS. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AONC Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AONC has a market cap of 331.1M. Regarding current trading prices, NVOS is priced at $0.00, while AONC trades at $11.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AONC's P/E ratio is -12.72. In terms of profitability, NVOS's ROE is -1.20%, compared to AONC's ROE of +0.25%. Regarding short-term risk, NVOS is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AIRS Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AIRS has a market cap of 315.8M. Regarding current trading prices, NVOS is priced at $0.00, while AIRS trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AIRS's P/E ratio is -17.45. In terms of profitability, NVOS's ROE is -1.20%, compared to AIRS's ROE of -0.21%. Regarding short-term risk, NVOS is more volatile compared to AIRS. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs TOIIW Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, TOIIW has a market cap of 226.6M. Regarding current trading prices, NVOS is priced at $0.00, while TOIIW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas TOIIW's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to TOIIW's ROE of -5.10%. Regarding short-term risk, NVOS is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs CSU Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, NVOS is priced at $0.00, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas CSU's P/E ratio is 0.67. In terms of profitability, NVOS's ROE is -1.20%, compared to CSU's ROE of +2.23%. Regarding short-term risk, NVOS is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs TOI Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, TOI has a market cap of 217.6M. Regarding current trading prices, NVOS is priced at $0.00, while TOI trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas TOI's P/E ratio is -3.49. In terms of profitability, NVOS's ROE is -1.20%, compared to TOI's ROE of -5.10%. Regarding short-term risk, NVOS is more volatile compared to TOI. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs JYNT Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, JYNT has a market cap of 186.5M. Regarding current trading prices, NVOS is priced at $0.00, while JYNT trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas JYNT's P/E ratio is -121.90. In terms of profitability, NVOS's ROE is -1.20%, compared to JYNT's ROE of -0.43%. Regarding short-term risk, NVOS is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs DCGO Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, DCGO has a market cap of 152.6M. Regarding current trading prices, NVOS is priced at $0.00, while DCGO trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas DCGO's P/E ratio is -154.00. In terms of profitability, NVOS's ROE is -1.20%, compared to DCGO's ROE of -0.00%. Regarding short-term risk, NVOS is more volatile compared to DCGO. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs BTMD Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, BTMD has a market cap of 152.4M. Regarding current trading prices, NVOS is priced at $0.00, while BTMD trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas BTMD's P/E ratio is 6.86. In terms of profitability, NVOS's ROE is -1.20%, compared to BTMD's ROE of -0.19%. Regarding short-term risk, NVOS is more volatile compared to BTMD. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs KDLYW Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, KDLYW has a market cap of 109.8M. Regarding current trading prices, NVOS is priced at $0.00, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas KDLYW's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to KDLYW's ROE of -1.46%. Regarding short-term risk, NVOS is more volatile compared to KDLYW. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs FVE Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, NVOS is priced at $0.00, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas FVE's P/E ratio is -5.64. In terms of profitability, NVOS's ROE is -1.20%, compared to FVE's ROE of -0.15%. Regarding short-term risk, NVOS is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs MODV Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, MODV has a market cap of 47.1M. Regarding current trading prices, NVOS is priced at $0.00, while MODV trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas MODV's P/E ratio is -0.20. In terms of profitability, NVOS's ROE is -1.20%, compared to MODV's ROE of +6.87%. Regarding short-term risk, NVOS is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs ALR Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, NVOS is priced at $0.00, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas ALR's P/E ratio is -1.11. In terms of profitability, NVOS's ROE is -1.20%, compared to ALR's ROE of -0.15%. Regarding short-term risk, NVOS is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs CCEL Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, CCEL has a market cap of 41.4M. Regarding current trading prices, NVOS is priced at $0.00, while CCEL trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas CCEL's P/E ratio is 512.50. In terms of profitability, NVOS's ROE is -1.20%, compared to CCEL's ROE of -0.01%. Regarding short-term risk, NVOS is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs IMAC Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, NVOS is priced at $0.00, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas IMAC's P/E ratio is -2.27. In terms of profitability, NVOS's ROE is -1.20%, compared to IMAC's ROE of +2.46%. Regarding short-term risk, NVOS is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs PIII Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, PIII has a market cap of 21.2M. Regarding current trading prices, NVOS is priced at $0.00, while PIII trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas PIII's P/E ratio is -0.12. In terms of profitability, NVOS's ROE is -1.20%, compared to PIII's ROE of -1.29%. Regarding short-term risk, NVOS is more volatile compared to PIII. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AIH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, NVOS is priced at $0.00, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AIH's P/E ratio is -2.78. In terms of profitability, NVOS's ROE is -1.20%, compared to AIH's ROE of +1.16%. Regarding short-term risk, NVOS is more volatile compared to AIH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs AMS Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, AMS has a market cap of 15.8M. Regarding current trading prices, NVOS is priced at $0.00, while AMS trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas AMS's P/E ratio is 11.67. In terms of profitability, NVOS's ROE is -1.20%, compared to AMS's ROE of +0.06%. Regarding short-term risk, NVOS is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs CANO Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, NVOS is priced at $0.00, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas CANO's P/E ratio is -0.01. In terms of profitability, NVOS's ROE is -1.20%, compared to CANO's ROE of -1.49%. Regarding short-term risk, NVOS is more volatile compared to CANO. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs FTRP Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, NVOS is priced at $0.00, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas FTRP's P/E ratio is -1.22. In terms of profitability, NVOS's ROE is -1.20%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, NVOS is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs GBNH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, NVOS is priced at $0.00, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas GBNH's P/E ratio is -0.06. In terms of profitability, NVOS's ROE is -1.20%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, NVOS is more volatile compared to GBNH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs MNDR Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, MNDR has a market cap of 5.3M. Regarding current trading prices, NVOS is priced at $0.00, while MNDR trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas MNDR's P/E ratio is -0.27. In terms of profitability, NVOS's ROE is -1.20%, compared to MNDR's ROE of -5.70%. Regarding short-term risk, NVOS is more volatile compared to MNDR. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs RHE Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, NVOS is priced at $0.00, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas RHE's P/E ratio is -1.79. In terms of profitability, NVOS's ROE is -1.20%, compared to RHE's ROE of +1.52%. Regarding short-term risk, NVOS is more volatile compared to RHE. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs ATIP Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, ATIP has a market cap of 4.4M. Regarding current trading prices, NVOS is priced at $0.00, while ATIP trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas ATIP's P/E ratio is -0.05. In terms of profitability, NVOS's ROE is -1.20%, compared to ATIP's ROE of +1.77%. Regarding short-term risk, NVOS is more volatile compared to ATIP. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs IMACW Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, NVOS is priced at $0.00, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas IMACW's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to IMACW's ROE of +2.46%. Regarding short-term risk, NVOS is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for NVOS.
NVOS vs IONM Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, IONM has a market cap of 1.7M. Regarding current trading prices, NVOS is priced at $0.00, while IONM trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas IONM's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to IONM's ROE of +0.75%. Regarding short-term risk, NVOS is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for NVOS.
NVOS vs NIVFW Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, NIVFW has a market cap of 1.3M. Regarding current trading prices, NVOS is priced at $0.00, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas NIVFW's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to NIVFW's ROE of -0.39%. Regarding short-term risk, NVOS is more volatile compared to NIVFW. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs SYRA Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, SYRA has a market cap of 967.1K. Regarding current trading prices, NVOS is priced at $0.00, while SYRA trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas SYRA's P/E ratio is -0.25. In terms of profitability, NVOS's ROE is -1.20%, compared to SYRA's ROE of -1.04%. Regarding short-term risk, NVOS is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs CCM Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, CCM has a market cap of 928.4K. Regarding current trading prices, NVOS is priced at $0.00, while CCM trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas CCM's P/E ratio is -0.65. In terms of profitability, NVOS's ROE is -1.20%, compared to CCM's ROE of +0.13%. Regarding short-term risk, NVOS is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs RHE-PA Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, RHE-PA has a market cap of 674.5K. Regarding current trading prices, NVOS is priced at $0.00, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, NVOS's ROE is -1.20%, compared to RHE-PA's ROE of +1.52%. Regarding short-term risk, NVOS is more volatile compared to RHE-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs BACK Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, BACK has a market cap of 189.2K. Regarding current trading prices, NVOS is priced at $0.00, while BACK trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas BACK's P/E ratio is -0.01. In terms of profitability, NVOS's ROE is -1.20%, compared to BACK's ROE of +2.46%. Regarding short-term risk, NVOS is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs PIIIW Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, PIIIW has a market cap of 27.8K. Regarding current trading prices, NVOS is priced at $0.00, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, NVOS's ROE is -1.20%, compared to PIIIW's ROE of -1.29%. Regarding short-term risk, NVOS is more volatile compared to PIIIW. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs SLHGP Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, NVOS's ROE is -1.20%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, NVOS is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs TLMDW Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas TLMDW's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, NVOS is more volatile compared to TLMDW. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs DCGOW Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas DCGOW's P/E ratio is N/A. In terms of profitability, NVOS's ROE is -1.20%, compared to DCGOW's ROE of -0.00%. Regarding short-term risk, NVOS is more volatile compared to DCGOW. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs NFH Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, NFH has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas NFH's P/E ratio is -19.75. In terms of profitability, NVOS's ROE is -1.20%, compared to NFH's ROE of -0.06%. Regarding short-term risk, NVOS is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs HNGR Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, HNGR has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas HNGR's P/E ratio is 19.71. In terms of profitability, NVOS's ROE is -1.20%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, NVOS is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs TVTY Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, TVTY has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas TVTY's P/E ratio is 19.06. In terms of profitability, NVOS's ROE is -1.20%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, NVOS is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs TLMD Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, TLMD has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas TLMD's P/E ratio is -1.60. In terms of profitability, NVOS's ROE is -1.20%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, NVOS is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs SLHG Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, SLHG has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas SLHG's P/E ratio is -1.48. In terms of profitability, NVOS's ROE is -1.20%, compared to SLHG's ROE of N/A. Regarding short-term risk, NVOS is more volatile compared to SLHG. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.
NVOS vs DVCR Comparison
NVOS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVOS stands at 43.4K. In comparison, DVCR has a market cap of 0. Regarding current trading prices, NVOS is priced at $0.00, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVOS currently has a P/E ratio of N/A, whereas DVCR's P/E ratio is 28.34. In terms of profitability, NVOS's ROE is -1.20%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, NVOS is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for NVOS.